Table 74, Description of sensitivity analysis (new strategy versus old strategy) - Cystic Fibrosis

Warning: The NCBI web site requires JavaScript to function. more...

Study/strategy	Pathogen	ICER
Study/strategy	Pathogen	Base case	1. Drug to treat chronic infection	2. Nebuliser cost	3. Utility of intermittent infection	4. Cost to treat an exacerbation	5. Shared Care model
Cohort segregation
France 2008	iBCC	Dominated	NA	NA	Dominated	NA	NA
Whitford 1995	iBCC	Dominant	NA	NA	Dominant	NA	Dominant
Federiksen 1999	iPA	£241,185	NA	£236,693	£123,541	NA	NA
Lee 2004 (prevalence)	iPA	Dominated	NA	Dominated	Dominated	NA	Dominated
Federiksen 1999	cPA	Dominant	Dominant	Dominant	NA	Dominant	NA
Hoiby 1989	cPA	Dominant	Dominant	Dominant	NA	Dominant	NA
Lee 2004 (prevalence)	cPA	Dominant	£19,021	Dominant	NA	£22,128	Dominant
Protective equipment
Savant 2014	iPA	Dominant	NA	Dominant	Dominant	NA	NA
Chen 2001	iBCC	Dominant	NA	NA	Dominant	NA	NA
Inpatient beds
Chen 2001	iBCC	Dominant	NA	NA	Dominant	NA	NA
France 2008	iBCC	Dominant	NA	NA	Dominant	NA	NA

: iBCC, intermittent B cepacia complex; iPA, intermittent P aeruginosa; ICER, incremental cost-effectiveness ratio; NA, not applicable

Cystic Fibrosis: Diagnosis and management.

NICE Guideline, No. 78.

National Guideline Alliance (UK).

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.